Skip to main content

Advertisement

Early recognition and treatment of neuropsychiatric symptoms to improve quality of life in early Alzheimer’s disease: protocol of the BEAT-IT study

Alzheimer's Research & Therapyvolume 11, Article number: 48 (2019) | Download Citation

Abstract

Background

Neuropsychiatric symptoms (NPS) are very common in patients with mild cognitive impairment (MCI) and Alzheimer’s disease (AD) dementia and are associated with various disadvantageous clinical outcomes including a negative impact on quality of life, caregiver burden, and accelerated disease progression. Despite growing evidence of the efficacy of (non)pharmacological interventions to reduce these symptoms, NPS remain underrecognized and undertreated in memory clinics. The BEhavioural symptoms in Alzheimer’s disease Towards early Identification and Treatment (BEAT-IT) study is developed to (1) investigate the neurobiological etiology of NPS in AD and (2) study the effectiveness of the Describe, Investigate, Create, Evaluate (DICE) approach to structure and standardize the current care of NPS in AD. By means of the DICE method, we aim to improve the quality of life of AD patients with NPS and their caregivers who visit the memory clinic. This paper describes the protocol for the intervention study that incorporates the latter aim.

Methods

We aim to enroll a total of 150 community-dwelling patients with MCI or AD and their caregivers in two waves. First, we will recruit a control group who will receive care as usual. Next, the second wave of participants will undergo the DICE method. This approach consists of the following steps: (1) describe the context in which NPS occur, (2) investigate the possible causes, (3) create and implement a treatment plan, and (4) evaluate whether these interventions are effective. Primary outcomes are the quality of life of patients and their caregivers. Secondary outcomes include NPS change, caregiver burden, caregivers’ confidence managing NPS, psychotropic medication use, the experiences of patients and caregivers who underwent the DICE method, and the cost-effectiveness of the intervention.

Conclusions

This paper describes the protocol of an intervention study that is part of the BEAT-IT study and aims to improve current recognition and treatment of NPS in AD by structuring and standardizing the detection and treatment of NPS in AD using the DICE approach.

Trial registration

The trial was registered on the Netherlands Trial Registry (NTR7459); registered 6 September 2018.

Introduction

Background and rationale

The majority of patients with Alzheimer’s disease (AD) experience neuropsychiatric symptoms (NPS) during the course of their disease [1, 2]. NPS include behaviors such as apathy, agitation, and psychosis, and are already highly prevalent in patients in the early stages of AD including those with mild cognitive impairment (MCI) [3]. NPS have a large impact on the quality of life (QoL) of patients and their caregivers [4], leading to extensive healthcare costs [5]. In addition, NPS are related to accelerated progression of the disease and earlier institutionalization [6, 7].

Although NPS are increasingly recognized as core features of AD [2], NPS are currently underrecognized during the diagnostic phase in memory clinics. This notion arises from our local experience, but one that has also been raised previously by several international research groups [8,9,10,11,12]. While cognitive testing and instrumental activities of daily living (IADL) questionnaires are typically administered during standard clinical work-up, assessment of NPS (e.g., using the Neuropsychiatric Inventory (NPI)) is often not [13]. The failure of clinicians to prioritize the assessment of NPS leads to undertreatment and a variety of associated suboptimal outcomes [14, 15]. This is clearly a missed opportunity since there is growing evidence for the efficacy of psychosocial and pharmacological interventions to reduce NPS and improve QoL in patients with AD [16,17,18,19].

NPS are often considered as medication targets in cases where NPS are appropriately detected by clinicians [11]. This leads to high rates of (off-label) psychotropic medication prescriptions that are only modestly effective in dementia [20]. In addition, this symptomatic treatment does not do justice to the multiple contributors causing NPS, including factors relating to the patient (e.g., personality), caregiver (e.g., communication style), and environment (e.g., safety) [11, 21, 22]. Therefore, a patient-centered care (PCC) approach is preferred that considers all these individual factors when managing NPS [1, 17, 23].

After a comprehensive assessment of NPS, nonpharmacological interventions are the first choice to treat NPS in dementia as recommended by the national and international guidelines on the diagnosis and treatment of dementia [24,25,26]. Although several psychosocial interventions have been developed and proven to be effective (e.g., [27,28,29]), these programs have rarely been implemented into standard care in memory clinics [10]. Previous studies have suggested various barriers to implementing these guidelines, including a lack of training and knowledge among clinicians regarding the efficacy, dosing, and timing of nonpharmacological interventions [22, 30]. Nonpharmacological strategies are also considered to be more time-consuming compared to psychotropic medication. Furthermore, there are only limited evidence-based interventions suitable for patients with early-stage dementia and their caregivers given the focus of previous research on institutionalized patients with severe dementia [31]. To overcome these barriers, there is a need for a tool that translates the current guidelines into clinical practice and integrates a comprehensive assessment into the standard work-up at memory clinics in order to improve early recognition and tailored treatment of NPS in AD.

Recently, a multidisciplinary expert panel proposed such a tool that integrates current models and theories on the causes of NPS to structure the assessment and management of these symptoms following four steps: Describe, Investigate, Create, Evaluate—i.e., the DICE method [10]. This framework identifies NPS, examines possible underlying causes, and consequently integrates pharmacological and nonpharmacological interventions to treat these symptoms following a PCC approach.

Similar approaches to the DICE method have been developed to address NPS in dementia (e.g., “Grip on Challenging Behaviour” [32], “4D Approach” [33], “Act in Case of Depression” [34], “STA OP!”) [35]. However, studies in community-dwelling patients are lacking, as the majority of these methods have been carried out in the nursing home setting. A recent pilot study showed that the use of the DICE method reduced caregiver distress in caregivers of community-dwelling patients with dementia [36] and supports the use of this approach in the outpatient setting. Moreover, the DICE method has been suggested as the most promising nonpharmacological approach to manage NPS in dementia [37]. Besides the evidence on its effectiveness, demonstrating the cost-effectiveness of the DICE method is crucial before this approach can be part of the standard care [18, 38].

The BEhavioral symptoms in Alzheimer’s disease Towards early Identification and Treatment (BEAT-IT) study is developed to increase our understanding of NPS across the spectrum of AD. This project aims to (1) investigate the etiology of the behavioral variant of AD (bvAD) [39] as a model of the neurobiological mechanisms of NPS in AD and (2) study the effectiveness of the DICE method for the management of NPS in patients with MCI and AD. This paper describes the protocol of an intervention study that focuses on the latter aim.

Objectives

The aim of this study is to use the DICE method to structure and standardize the recognition of NPS in AD in the memory clinic, implement current guidelines for the treatment of NPS in MCI and AD, and to investigate the effects of the treatment on QoL. Note that we will not evaluate the treatments itself (e.g., the efficacy of psychosocial interventions or antidepressants) since those are already evidence-based interventions recommended by current guidelines, but rather examine the benefits of structuring these interventions in the context of the memory clinic. We will do this by investigating the effectiveness and cost-effectiveness of the DICE method in community-dwelling patients with AD or MCI visiting the memory clinic and compare this group to a control group who will receive care as usual (CAU). We hypothesize that the structuring and standardization of the care of NPS with the use of the DICE approach will improve the QoL of both caregivers and patients at the early stages of AD. In addition, implementing the DICE method is expected to allow early recognition of NPS and reduce NPS, caregiver burden, and psychotropic drug use, and is aimed to be cost-effective. By doing so, this study may contribute to the improvement of early identification and management of NPS in AD in memory clinics.

Methods

The Standard Protocol Items: Recommendations for Interventions Trials (SPIRIT) guidelines were followed for this protocol [40].

Study design

This study is a prospective multicenter study with a quasi-experimental design (see Fig. 1). In the first part of the study, a control group will be recruited who will receive CAU. After 1 year, we will enroll the second wave of participants who will receive a structured and standardized assessment and treatment of NPS based on the principles of the DICE method. Hence, the enrollment of the control group will be completed before the start of the inclusion of the intervention group. This design has the advantage that it reduces the risk of contamination and crossover between the two groups. Moreover, a crossover design is not possible given the progressive nature of AD. Furthermore, cluster randomization of hospitals is not feasible because of the differences in CAU between the sites. Since patients of both waves will be enrolled in the same sites, we assume that the waves will not show meaningful differences in demographic and clinical characteristics. Also, no substantial changes are expected in the upcoming years regarding current CAU in the memory clinics based on the view of collaborating experts and the organization of care in the last years.

Fig. 1
figure1

Design of the BEAT-IT study. Note that only the assessments are depicted since intervention visits will vary across subjects in the intervention group due to the personalized approach

Full size image

Subjects will be followed for 6 months while undergoing three assessments during this period. The primary outcome will be the QoL of patients and their caregivers. Secondary outcomes include changes in the prevalence and severity of NPS, caregiver burden, caregivers’ confidence managing NPS, psychotropic medication use, the experiences of patients and caregivers who underwent the DICE method, and the cost-effectiveness of the intervention.

Eligibility criteria

In order to be eligible to participate in this study, patients must meet all of the following criteria (see Table 1): (a) a clinical diagnosis of probable AD (NIA-AA criteria by McKhann et al. [41]) or MCI due to AD (NIA-AA criteria by Albert et al. [42]) with at least intermediate probability of AD etiology based on: patient history, neuropsychological assessment [43], and neuroimaging (magnetic resonance imaging (MRI) or positron-emission tomography (PET)). The clinical diagnosis needs to be established within the last 2 years so that patients with a diagnosis who visit the memory clinic for clinical follow-up might also participate; (b) presence of NPS established with the Neuropsychiatric Inventory Questionnaire (NPI-Q, presence of ≥ 1 symptoms) administered within the last month [44]; (c) a Mini-Mental State Examination (MMSE) score > 15 so that patients are able to reflect on their QoL [45]; (d) patients need to be community-dwelling; and (e) availability of a reliable informant who is considered to be the primary caregiver.

Table 1 Eligibility criteria
Full size table

A potential subject who meets any of the following criteria will be excluded from participation in this study: (a) patients meet the (additional) criteria of any non-AD neurodegenerative disease, except vascular co-pathology; (b) legally incapable (as judged by the attending physician and therefore unable to give a written consent; (c) evidence of current delirium or previous delirium in the past 6 months; (d) primary (premorbid) psychiatric disorders such as schizophrenia or bipolar disorder that could better explain the manifestation of NPS, or current abuse of alcohol or drugs; and (e) currently participating in a clinical trial. Patients are allowed to be on medication (e.g., acetylcholinesterase inhibitors or psychotropic drugs) prior to inclusion since no differences between the two waves are expected regarding the medication use at baseline, and this will be carefully documented in a case report form (CRF).

Recruitment

Patients will be recruited from six different memory clinics in and around Rotterdam in the Netherlands (Erasmus University Medical Center, Franciscus Gasthuis & Vlietland, Het Van Weel-Bethesda Ziekenhuis, Maasstad Hospital, and Spijkenisse Medical Center) to facilitate patient enrollment and guarantee a good mixture of patients from both academic and general hospitals.

After a diagnosis of MCI or AD dementia is established at one of the memory clinics, study eligibility will be evaluated based on the in- and exclusion criteria by the local attending physician. Alternatively, patients already diagnosed with MCI or AD dementia who visit the memory clinic for clinical follow-up will also be identified based on these criteria.

Interventions

Control group

Participants in the control group will receive CAU at their local hospital. We expect that the CAU will be quite heterogeneous over sites and may consist of psychoeducation about dementia by a nurse or consultant specialized in dementia, the prescription of psychotropic drugs, and/or the referral to a psychiatric outpatient clinic for specialized treatment in patients with severe NPS [46]. Because of these differences, we will carefully keep track of the procedures undertaken by clinicians for patients in the CAU group. Based on recommendations for assessing usual care in clinical trial [47], we will develop a study-specific CRF that will be filled out at the time of enrolment and will be updated at each follow-up visit.

Intervention group

All participants in the second wave will be enrolled in the intervention group. In this group, we will apply the DICE method to structure and standardize the assessment and management of NPS. Participants who withdraw from study participation after being informed by their physician and/or the researchers will receive CAU at their hospital as described above. The DICE method will take place at the Neurology Department of the Erasmus MC and will be carried out by a psychiatrist (MC) and neuropsychologists (EB, WSE, JMP) who are all involved in the memory clinic of this department.

The steps of the DICE method are depicted in Fig. 2. More detailed information on the development and background of the DICE method can be found elsewhere [10]. During the first visit, the patient and caregiver will undergo a consultation by an experienced psychiatrist to establish clinically relevant NPS (Describe). Factors related to the patient, caregiver, and environment will be examined following the DICE method [22, 48] and the DICE manual [49]. For factors related to the patient, we will record the chronic somatic conditions using the Cumulative Illness Rating Scale for Geriatrics (CIRS-G) [50] semi-structured interview, followed by a clinical examination to explore the medication changes, pain, sleep hygiene, and sensory changes. If necessary, a lab evaluation will be conducted to screen for infections, thyroid problems, and metabolic disorders. Other patient-related factors including unmet needs, boredom, and emotional well-being will be assessed using the Checklist of Factors to Consider to Identify Potential Causes of Behavioral Symptoms developed by Gitlin et al. [48]. Caregiver-related factors will be screened by using the Relationship Closeness Scale [51], Center for Epidemiologic Studies Depression Scale [52], and the CareQol-7D [53]. This will be extended by history taking on family and cultural expectations, knowledge about dementia, and the availability of support. Environmental factors will be assessed to the patient and caregiver by the Informal Assessment: Brief Questions to Guide Describing Behavioral Symptoms [48]. A full and accurate description of specific behavior will provide more insight about the “who, when, where, and what” about the situations in which the behavior is occurring, while taking safety risks and the level of physical and social stimulation into account (Investigate). Thereafter, a multidisciplinary meeting will take place in which a personalized treatment advice is formulated based on the current guidelines on the diagnosis and assessment of NPS in dementia (Create) [24,25,26]. During the second visit, this treatment advice is discussed and adjusted to the needs, values, and characteristics of the patient and caregiver following a PCC approach. Given the large heterogeneity in symptoms, interventions will vary for each individual and can include psychoeducation, psychosocial interventions, caregiver support, and/or pharmacological treatment based on the current (inter)national guidelines [24,25,26, 54,55,56]. Notably, the interventions and strategies that will be used to reduce NPS and enhance the QoL are all evidence-based treatment strategies that are or should be carried out in the current clinical practice. Finally, we will monitor treatment progression 1 month after the last visit by telephone (Evaluate). Patients and their caregivers are then invited for an extra visit if necessary. In such cases, alternative interventions will be discussed if planned interventions were not implemented or effective. Additional diagnostic procedures or interventions will be monitored in the CRF.

Fig. 2
figure2

The DICE method with examples of questions and actions. Adapted from Kales et al. [10] and Gitlin et al. [48]

Full size image

Outcome measures

For the control group, measurements will take place at baseline (T0), with follow-up testing at 3 months (T1) and 6 months (T2). For the intervention group, measurements will take place at baseline (T0), directly after treatment (T1), and follow-up at 6 months (T2). The T1 measurements will be planned after finishing the (psychosocial) intervention and/or when medication is stabilized and thus may vary between subjects in the intervention group. We will gather all relevant clinical and intervention-related information which enables us to study post hoc whether this variation in T1 assessments may have resulted in bias. All measurements will take place at the local hospitals or at the patients’ homes, see Table 2 for an overview of all outcome measures.

Table 2 Outcome measures
Full size table

Primary outcomes

The QoL of the patient will be measured by the Quality of Life in Alzheimer’s Disease (QoL-AD) questionnaire [67]. This is one of the most widely used QoL questionnaires in AD and has good psychometric properties [80]. Patients are questioned via a 13-item interview format. The proxy version of the QoL-AD is also used and filled out by the caregiver since previous studies have shown that the caregivers’ perspective on the patients’ QoL might be a more valid indicator of treatment success [81].

The CarerQol-7D will be used to measure the care-related QoL in caregivers [53]. The instrument includes six burden dimensions and a subjective valuation scale for happiness.

Secondary outcomes

Changes in NPS will be assessed with the NPI-Q [44], a general screening questionnaire including 12 distinct NPS. For each item, caregivers have to indicate the presence, the severity, and the extent of emotional distress that each symptom causes. Similar to Gitlin et al. [69], we will add a frequency score and will ask caregivers how confident they are in managing a certain symptom on a 5-point Likert scale (0 = not confident to 4 = extremely confident).

A two-step approach will be used to further assess NPS: if certain symptoms are present, as indicated by an NPI-Q frequency score ≥ 1, specific questionnaires will be used to assess these symptoms in more detail. All instruments will be administered to the caregiver. To measure the depressive symptoms, the Dutch version of the Cornell Scale for Depression in Dementia (CSDD) will be used [76]. The CSSD consists of 19 items covering mood, behavioral changes, and circadian changes related to depression and is validated in patients with dementia [76]. Anxiety symptoms will be measured by the Rating Anxiety in Dementia (RAID) scale, an 18-item inventory that includes specific fears and somatic symptoms related to anxiety [77]. Agitation, irritability, aggression, and motor disturbances will be measured by the Dutch version of the Cohen-Mansfield Agitation Inventory (CMAI-D) [82]. Hallucinations will be assessed by the subscale B of the Behavioral Pathology in Alzheimer’s Disease Rating Scale (BEHAVE-AD) [78], and delusions will be assessed by the subscale A of the BEHAVE-AD. Apathy is assessed with the informant-reported Apathy Evaluation Scale (AES-I) [75] and comprises of 18 items. Sleep disturbances will be measured by the 8-item Sleep Disorder Inventory (SDI) [79], an expanded version of the sleep disturbances item of the NPI. Similar to the NPI, caregivers have to score each symptom of the SDI on frequency, severity, and caregiver distress.

Caregiver burden will be measured with the perseverance time, a one-item questionnaire that assesses caregiver burden by asking the period of time (in months) that the informal caregiver thinks he or she is able to maintain the care if the current situation remains stable [68]. This questionnaire is a good predictor for institutionalization [83].

The Clinical Dementia Rating Scale (CDR), MMSE, and a neuropsychological assessment will be administered during the diagnostic procedure at the local memory clinic prior to inclusion. The CDR includes six domains covering cognitive function and IADL associated with dementia [57]. Disease severity will be determined based on clinical diagnosis and CDR global score with MCI due to AD (CDR score 0.5), mild AD dementia (CDR score 1), and moderate to severe AD dementia (CDR score 2–3). Global cognitive function will be measured with the MMSE [58]. The neuropsychological assessment will be carried out according to the Dutch Parelsnoer Institute for Neurodegenerative Diseases [40] and covers the major cognitive domains including memory, attention, processing speed, language, visuospatial abilities, and executive functioning.

The Amsterdam Instrumental Activities of Daily Living Questionnaire (A-IADL-Q) is a proxy measure to detect problems in IADL in patients with dementia [66]. This tool is a reliable and valid instrument to detect changes in IADL over time.

Physical health and comorbidities of the patient will be assessed using the CIRS-G [50]. The severity of 14 common medical problems in the geriatric population (e.g., heart, liver, vascular diseases) will be judged by one of the researchers during a short interview with the patient and caregiver.

Psychotropic medication use will be documented in the CRF. The total number of medications used will be registered and classified according to the ATC coding: antidepressants, antipsychotics, hypnotics and sedatives, anxiolytics, and anti-dementia medications [20].

Cost-effectiveness

For the cost-effectiveness evaluation, patients will complete the EQ-5D-5 L, the most commonly used health-related QoL instrument [70], and the ICEpop CAPability measure for Older people (ICECAP-O), a 5-item well-being scale [71], and caregivers will fill out the CarerQol-7D. In addition, the Institute for Medical Technology Assessment Valuation of Informal Care Questionnaire (iMTA iVICQ) [72] will be used to assesses the amount, costs, and appraisal of the care provided by the caregivers. The iMTA Medical Consumption Questionnaire (iMTA MCQ) consists of 31 questions regarding healthcare utilization [73] and incorporates direct healthcare use of the patient. Both the iMTA MCQ and the iMTA iVICQ will be sent to the caregivers and can be completed at home.

Qualitative endpoint data

A random selection of one out of four of the dyads in the intervention group will be invited to participate in the qualitative part of this study, accounting for the site and disease stage. Semi-structured interviews will be conducted in order to achieve more insight into the experiences of participants who underwent the DICE method and what they considered as helpful elements. The interviews will be conducted face-to-face, will be audio-taped, and will last approximately 60 min. Interviews will be performed until saturation is reached, i.e., until no new concepts and themes are obtained [84], which we estimate to reach after we interviewed 15–20 patients with their caregivers [8, 85, 86]. Questions will be asked in an open non-directive manner, focusing on the subjects’ thoughts, feelings, and experiences. Topics include the subjects’ experience of the intervention, and which elements were considered to be effective and which not, with the aim to examine the efficacy of and experiences with the DICE method from the perspective of patients and caregivers.

Sample size

In order to reach sufficient power to detect reliable and clinically relevant changes, we performed a power calculation using G*Power. The power calculation is based on the results of a recent meta-analysis by Kim and Park [17], on the effectiveness of PCC in a mix of institutionalized and community-dwelling patients, and the results of a pilot study on the effectiveness of the DICE method in community-dwelling patients and caregivers [36]. Both studies showed a moderate effect size for the effects of PCC interventions on QoL in patients with AD and their caregivers when compared to CAU. Since there are limited validated sample size calculation methods for the mixed model approach we aim to use [87], our calculation is based on a repeated measures ANOVA. Using G*Power, the required sample sizes were N = 86 and N = 46 for between- and within-group analyses, respectively, based on a power of 0.80 and an alpha of 0.05. After enquiry, the 6 recruitment centers suggested that at least 25 patients receive a MCI or AD diagnosis annually at each site. Though there are a high number of patients available at all 6 study sites, the participation of eligible dyads is expected to be 150 since not all patients will fulfill our criteria or will be willing to participate (based on an estimated inclusion rate of 40% [88]). We will carefully keep track of the reasons why eligible subjects refuse to participate. We will recruit a total of 150 patients during the total inclusion period of approximately 3 years (N = 75 in the control group and N = 75 in the intervention group), which exceeds the estimated needed sample size, even when accounting for dropout/loss to follow-up.

Statistical methods

T-tests or chi-square tests will be used to identify the differences in baseline characteristics (e.g., age, education level, disease severity) between the control group and the intervention group. For the primary and secondary study outcomes, we will use an intention-to-treat approach including all subjects irrespective of the adherence to our intervention [89]. Thereafter, we will perform per-protocol analyses with only the subjects who completed the intervention (underwent all DICE steps). We will correct for multiple testing.

We will use the Little’s Missing Completely at Random Test to examine whether the data are missing at random or missing completely at random. The mixed model analyses will be able to handle the data when the missing data is completely at random. Multiple imputation will be used in cases when data is missing at random.

Linear mixed models will be used for the primary and secondary outcomes for the T0, T1, and T2 time points. These statistics are preferred when using longitudinal data because of its advantage in handling missing data and its capacity to deal with nested data and variance in follow-up duration between and within the groups. Changes in the trajectories of the primary and secondary outcomes are compared between the two groups. Subject, hospital, and time are considered as random effects, and baseline measure, group, and disease severity are accounted as fixed effects.

We will perform a cost-utility analysis of the intervention group versus the control group in accordance with the Dutch guidelines for economic evaluations on the basis of questionnaires [90].

Quality and length of life will be combined into quality-adjusted life years (QALYs) using a Markov model to extrapolate lifetime outcomes based on the data from this study combined with literature data. The EQ-5D-5 L, ICECAP-O, and CarerQol-7D data will be transformed into QALYs for patients and caregivers (well-being years for ICECAP-O), using published tariffs obtained from general reference populations [90, 91].

With the simple Markov model, we will calculate the incremental effectiveness of the DICE method versus the control group in QALYs, incremental costs, and the incremental cost-effectiveness ratios. We will also perform one-way, two-way, and probabilistic sensitivity analyses to determine the effect of uncertainty in all input parameters. Using a non-parametric bootstrapping (randomly drawing 5000 observations with replacement from the patient sample), the degree of uncertainty for costs and health effects and the cost-utility ratio will be depicted. In addition, an acceptability curve will be drawn, which indicates the probability that the intervention studied has lower incremental costs per QALY gained than various thresholds.

A budget impact analysis will be performed that includes relevant features and tariffs of the Dutch healthcare system; anticipated uptake of the new intervention as well as usual care will be considered. The budget impact per year of implementing the new intervention will be estimated. All elements of medical costs for the intervention group and the control group will be considered and calculated.

Qualitative analyses

The audiotapes of all interviews will be transcribed verbatim. This data will be analyzed by two independent researchers with ATLAS.ti 7 software according to the thick analysis approach [92]. This approach endorses multiple triangulations, i.e., the use of multiple interpreters and techniques to analyze the data, to enhance validity.

The coding and analyses will be an iterative process simultaneously with the interviews, allowing adjustment of questions and topics. We will make use of open coding, thematic coding, and causal coding [93]. Open coding is an explorative process in which all elements of the data are coded. Thematic coding is a more deductive technique that included the coding of themes and categories that are proposed by the researchers prior to the analysis or emerge from the material and are considered to be of importance by the researchers. Causal coding will help us to get more insight into the working elements of the DICE approach as proposed by the participants. Characteristics of patients and their caregivers (age, sex, relationship, disease severity) will be used for descriptive purposes.

Discussion

The current paper describes the protocol of the BEAT-IT study, a multicenter study designed to investigate the effectiveness of a comprehensive assessment and personalized treatment of NPS in AD, following the DICE method to improve the QoL in patients with MCI and AD in the memory clinic. We hypothesize that early recognition and tailored treatment of NPS will benefit the QoL of patients and their caregivers; will reduce NPS, caregiver burden, and psychotropic drug use; and will lead to cost-effective care.

The novelty of this study lies in the inclusion of the whole spectrum of NPS, the enrollment of both patients with MCI and AD, and the evaluation of an approach that integrates both nonpharmacological and pharmacological interventions in the memory clinic setting. Besides standardized quantitative measures, a qualitative approach will be used to examine its efficacy and feasibility from the perspective of caregivers and patients. Also, important additional information will be obtained from studying the first wave of participants, enabling us to examine “naturalistic” progression of NPS and its relationship with other clinical measures. Insight in the current CAU of NPS will aid us in the formulation of recommendations to improve the daily clinical practice regarding the care of NPS in AD. After establishing the effectivity of the DICE method in the memory clinic setting, a next step would be to examine the implementation of this approach at other sites by taking already suggested and unique local barriers into account.

At the time of writing, recruitment is ongoing and is expected to be completed in December 2019 for the control group. Hereafter, the intervention group will be enrolled until the beginning of 2021, and follow-up measures will be completed in autumn 2021. Results will be available in late 2021.

There are a few possible threats to this study. Firstly, the use of the NPI-Q to screen for eligible patients might introduce an observer bias since this measure is not part of the regular diagnostic workup at some sites. Consequently, NPS may be detected more often, resulting in care that may not fully reflect the current CAU, i.e., underestimating the expected underrecognition and undertreatment of NPS in AD. Second, the current guidelines consider psychosocial interventions as the first-line treatment but mainly suggest interventions that may be more suitable for institutionalized patients with severe dementia, e.g., reminiscence therapy, aromatherapy, or “snoezelen” [24, 25]. Although various nonpharmacological interventions have been shown to be effective in community-dwelling patients [18], these strategies are rarely mentioned in the guidelines and therefore not integrated in clinical practice [94]. For our interventions, we will select nonpharmacological strategies based on prior studies (e.g., [48]) and our clinical expertise. Third, our outcome measures are mainly based on self-reported questionnaires that may not fully capture all effective aspects of the intervention [95, 96]. Moreover, patients with dementia may have difficulties completing the QoL questionnaires (EQ-5D-5 L, ICECAP-O) due to cognitive problems [97]. To circumvent some of these problems, we will also use qualitative research methods which enables us to better understand and measure the QoL of patients and to give participants the opportunity to express their experiences with the DICE method in an unrestricted manner. Fourth, the substantial differences across sites in CAU might be a challenge to this study, as patients visiting certain sites may receive more and different treatments compared to other centers. We will therefore aim to record all valuable information through our CRF, which enables us to perform post hoc sensitivity analyses, and verify whether this heterogeneity might affect the results. A final issue might be that patients are included based on clinical diagnostic criteria, without the use of AD pathophysiological biomarkers (e.g., abnormal levels of Aβ or tau proteins in CSF or on PET). Despite the fact that an MRI or (FDG-)PET scan of the brain is required, this may lead to the inclusion of patients who do not have underlying AD pathology, especially in those with MCI. However, the applied diagnostic criteria resemble those that are used in clinical practice where AD pathophysiological biomarkers are not part of the standard diagnostic workup. In addition, since this is a clinical study targeting clinical symptoms rather than the underlying disease process, we argue that the effects might be similar in patients with other underlying etiologies. We will however perform a sensitivity analysis in a subgroup of patients with positive AD biomarkers in order to study whether the effects are similar in this subgroup compared to the whole study group.

To conclude, the BEAT-IT study as a whole will increase our knowledge of the underlying neurobiology of NPS in AD, which may enable us to identify potential targets for therapeutic agents. The intervention study might provide evidence on how to structure and standardize the care of NPS in AD to improve the QoL of both caregivers and patients. Moreover, the findings of the intervention study will result in recommendations to improve the early detection and treatment of NPS in AD in the memory clinic.

Abbreviations

AD:

Alzheimer’s disease

AES-I:

Apathy Evaluation Scale Information version

A-IADL-Q:

Amsterdam Instrumental Activities of Daily Living Questionnaire

BEHAVE-AD:

Behavioral Pathology in Alzheimer’s Disease Rating Scale

bvAD:

Behavioral variant of AD

CAU:

Care as usual

CDR:

Clinical Dementia Rating Scale

CIRS-G:

Cumulative Illness Rating Scale for Geriatrics

CMAI-D:

Dutch version of Cohen-Mansfield Agitation Inventory

CRF:

Care report form

CSDD:

Cornell Scale for Depression in Dementia

CSF:

Cerebrospinal fluid

FDG-PET:

Fluorodeoxyglucose positron-emission tomography

IADL:

Instrumental activity of daily living

ICECAP-O:

ICEpop CAPability measure for Older people

iMTA iVICQ:

Institute for Medical Technology Assessment Valuation of Informal Care Questionnaire

iMTA MCQ:

Institute for Medical Technology Assessment Medical Consumption Questionnaire

MCI:

Mild cognitive impairment

MMSE:

Mini-Mental State Examination

MRI:

Magnetic resonance imaging

NPI-Q:

Neuropsychiatric Inventory Questionnaire

NPS:

Neuropsychiatric symptoms

PCC:

Patient-centered care

PET:

Positron-emission tomography

QALY:

Quality-adjusted life years

QoL:

Quality of life

QoL-AD:

Quality of Life in Alzheimer’s Disease questionnaire

RAID:

Rating Anxiety in Dementia

SDI:

Sleep Disorder Inventory

References

  1. 1.

    Geda YE, Schneider LS, Gitlin LN, Miller DS, Smith GS, Bell J, et al. Neuropsychiatric symptoms in Alzheimer’s disease: past progress and anticipation of the future. Alzheimers Dement. 2013;9(5):602–8.

  2. 2.

    Lyketsos CG, Carrillo MC, Ryan JM, Khachaturian AS, Trzepacz P, Amatniek J, et al. Neuropsychiatric symptoms in Alzheimer’s disease. Alzheimers Dement. 2011;7(5):532–9.

  3. 3.

    Wadsworth LP, Lorius N, Donovan NJ, Locascio JJ, Rentz DM, Johnson KA, et al. Neuropsychiatric symptoms and global functional impairment along the Alzheimer’s continuum. Dement Geriatr Cogn Disord. 2012;34(2):96–111.

  4. 4.

    Banerjee S, Smith SC, Lamping DL, Harwood RH, Foley B, Smith P, et al. Quality of life in dementia: more than just cognition. An analysis of associations with quality of life in dementia. JNNP. 2006;77(2):146–8.

  5. 5.

    Maust DT, Kales HC, McCammon RJ, Blow FC, Leggett A, Langa KM. Distress associated with dementia-related psychosis and agitation in relation to healthcare utilization and costs. Am J Geriatr Psychiatry. 2017;25(10):1074–82.

  6. 6.

    Tschanz JAT, Corcoran CD, Schwartz S, Treiber K, Green RC, Norton MC, et al. Progression of cognitive, functional and neuropsychiatric symptom domains in a population cohort with Alzheimer’s dementia: the Cache County Dementia Progression Study. Am J Geriatr Psychiatry. 2011;19(6):532–42.

  7. 7.

    Yaffe K, Fox P, Newcomer R, Sands L, Lindquist K, Dane K, et al. Patient and caregiver characteristics and nursing home placement in patients with dementia. JAMA. 2002;287(16):2090–7.

  8. 8.

    Braun A, Trivedi DP, Dickinson A, Hamilton L, Goodman C, Gage H, et al. Managing behavioural and psychological symptoms in community dwelling older people with dementia: 2. A systematic review of qualitative studies. Dementia (London). 2018.

  9. 9.

    Halpern R, Seare J, Tong J, Hartry A, Olaoye A, Aigbogun MS. Using electronic health records to estimate the prevalence of agitation in Alzheimer disease/dementia. Int J Geriatr Psychiatry. 2019;34(3):420–31.

  10. 10.

    Kales HC, Gitlin LN, Lyketsos CG, Detroit Expert Panel on A, Management of Neuropsychiatric Symptoms of D. Management of neuropsychiatric symptoms of dementia in clinical settings: recommendations from a multidisciplinary expert panel. J Am Geriatr Soc. 2014;62(4):762–9.

  11. 11.

    Kolanowski A, Fortinsky RH, Calkins M, Devanand DP, Gould E, Heller T, et al. Advancing research on care needs and supportive approaches for persons with dementia: recommendations and rationale. J Am Med Dir Assoc. 2018;19(12):1047–53.

  12. 12.

    Lanctot KL, Amatniek J, Ancoli-Israel S, Arnold SE, Ballard C, Cohen-Mansfield J, et al. Neuropsychiatric signs and symptoms of Alzheimer’s disease: new treatment paradigms. Alzheimers Dement (N Y). 2017;3(3):440–9.

  13. 13.

    Ismail Z, Mortby ME. Cognitive and neuropsychiatric screening tests in older adults. In: Chiu H, Shulman K, editors. Mental health and illness of the elderly. Singapore: Springer Singapore; 2017.

  14. 14.

    Eikelboom WS, van Rooij JGJ, van den Berg E, Coesmans M, Jiskoot LC, Singleton E, et al. Neuropsychiatric symptoms complicating the diagnosis of Alzheimer’s disease: a case report. J Alzheimers Dis. 2018;66(4):1363–9.

  15. 15.

    Woolley JD, Khan BK, Murthy NK, Miller BL, Rankin KP. The diagnostic challenge of psychiatric symptoms in neurodegenerative disease; rates of and risk factors for prior psychiatric diagnosis in patients with early neurodegenerative disease. J Clin Psychiatry. 2011;72(2):126–33.

  16. 16.

    Orgeta V, Qazi A, Spector A, Orrell M. Psychological treatments for depression and anxiety in dementia and mild cognitive impairment: systematic review and meta-analysis. Br J Psychiatry. 2015;207(4):293–8.

  17. 17.

    Kim SK, Park M. Effectiveness of person-centered care on people with dementia: a systematic review and meta-analysis. Clin Interv Aging. 2017;12:381.

  18. 18.

    Trivedi DP, Braun A, Dickinson A, Gage H, Hamilton L, Goodman C, et al. Managing behavioural and psychological symptoms in community dwelling older people with dementia: 1. A systematic review of the effectiveness of interventions. Dementia (London). 2018.

  19. 19.

    Wang J, Yu J-T, Wang H-F, Meng X-F, Wang C, Tan C-C, et al. Pharmacological treatment of neuropsychiatric symptoms in Alzheimer’s disease: a systematic review and meta-analysis. J Neurol Neurosurg Psychiatry. 2014;86:101–9.

  20. 20.

    Maust DT, Langa KM, Blow FC, Kales HC. Psychotropic use and associated neuropsychiatric symptoms among patients with dementia in the USA. Int J Geriatr Psychiatry. 2017;32(2):164–74.

  21. 21.

    Tible OP, Riese F, Savaskan E, von Gunten A. Best practice in the management of behavioural and psychological symptoms of dementia. Ther Adv Neurol Disord. 2017;10(8):297–309.

  22. 22.

    Kales HC, Gitlin LN, Lyketsos CG. Assessment and management of behavioral and psychological symptoms of dementia. BMJ. 2015;350(7).

  23. 23.

    Cohen-Mansfield J. Heterogeneity in dementia: challenges and opportunities. Alzheimer Dis Assoc Disord. 2000;14(2):60–3.

  24. 24.

    Zuidema SU, Smalbrugge M, Bil WME, Geelen R, Kok RM, Luijendijk HJ, et al. Multidisciplinary guideline problem behavior in dementia. Utrecht: Verenso, NIP; 2018.

  25. 25.

    International Psychogeriatric Association. The IPA Complete Guides to Behavioral and Psychological Symptoms of Dementia - Specialists Guide. Draper B, Henry B, Sanford FI, editors 2012.

  26. 26.

    National Institute for Health and Care Excellence. Dementia: assessment, management and support for people living with dementia.2018.

  27. 27.

    Gitlin LN, Arthur P, Piersol C, Hessels V, Wu SS, Dai Y, et al. Targeting behavioral symptoms and functional decline in dementia: a randomized clinical trial. J Am Geriatr Soc. 2018;66(2):339–45.

  28. 28.

    Gitlin LN, Winter L, Dennis MP, Hodgson N, Hauck WW. Targeting and managing behavioral symptoms in individuals with dementia: a randomized trial of a nonpharmacologic intervention. J Am Geriatr Soc. 2010;58(8):1465–74.

  29. 29.

    Belle SH, Burgio L, Burns R, Coon D, Czaja SJ, Gallagher-Thompson D, et al. Enhancing the quality of life of dementia caregivers from different ethnic or racial groups: a randomized, controlled trial. Ann Intern Med. 2006;145(10):727–38.

  30. 30.

    Brodaty H, Arasaratnam C. Meta-analysis of nonpharmacological interventions for neuropsychiatric symptoms of dementia. Am J Psychiatry. 2012;169(9):946–53.

  31. 31.

    Cohen-Mansfield J, Juravel-Jaffe A, Cohen A, Rasooly I, Golander H. Physicians’ practice and familiarity with treatment for agitation associated with dementia in Israeli nursing homes. Int Psychogeriatr. 2013;25(2):236–44.

  32. 32.

    Zwijsen SA, Smalbrugge M, Eefsting JA, Twisk JWR, Gerritsen DL, Pot AM, et al. Coming to grips with challenging behavior: a cluster randomized controlled trial on the effects of a multidisciplinary care program for challenging behavior in dementia. J Am Med Dir Assoc. 2014;15(7):531. e1–e10.

  33. 33.

    Rabins PV, Lyketsos CG. Practical dementia care. New York: Oxford University Press; 2006.

  34. 34.

    Leontjevas R, Gerritsen DL, Smalbrugge M, Teerenstra S, Vernooij-Dassen MJ, Koopmans RT. A structural multidisciplinary approach to depression management in nursing-home residents: a multicentre, stepped-wedge cluster-randomised trial. Lancet. 2013;381(9885):2255–64.

  35. 35.

    Pieper MJ, Francke AL, van der Steen JT, Scherder EJ, Twisk JW, Kovach CR, et al. Effects of a stepwise multidisciplinary intervention for challenging behavior in advanced dementia: a cluster randomized controlled trial. J Am Geriatr Soc. 2016;64(2):261–9.

  36. 36.

    Kales HC, Gitlin LN, Stanislawski B, Myra Kim H, Marx K, Turnwald M, et al. Effect of the WeCareAdvisor™ on family caregiver outcomes in dementia: a pilot randomized controlled trial. BMC Geriatr. 2018;18(1):113.

  37. 37.

    Kales HC, Lyketsos CG, Miller EM, Ballard C. Management of behavioral and psychological symptoms in people with Alzheimer’s disease: an international Delphi consensus. Int Psychogeriatr. 2018;31(1):83–90.

  38. 38.

    Detsky AS, Laupacis A. Relevance of cost-effectiveness analysis to clinicians and policy makers. JAMA. 2007;298(2):221–4.

  39. 39.

    Ossenkoppele R, Pijnenburg YA, Perry DC, Cohn-Sheehy BI, Scheltens NM, Vogel JW, et al. The behavioural/dysexecutive variant of Alzheimer’s disease: clinical, neuroimaging and pathological features. Brain. 2015;138(Pt 9:2732–49.

  40. 40.

    Chan A, Tetzlaff JM, Altman DG, et al. Spirit 2013 statement: defining standard protocol items for clinical trials. Ann Intern Med. 2013;158(3):200–7.

  41. 41.

    McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR, Kawas CH, et al. The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association Workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7(3):263–9.

  42. 42.

    Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, et al. The diagnosis of mild cognitive impairment due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association Workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7(3):270–9.

  43. 43.

    Aalten P, Ramakers IHGB, Biessels GJ, De Deyn PP, Koek HL, OldeRikkert MGM, et al. The Dutch Parelsnoer Institute-Neurodegenerative Diseases; methods, design and baseline results. BMC Neurol. 2014;14(1):254.

  44. 44.

    Kaufer DI, Cummings JL, Ketchel P, Smith V, MacMillan A, Shelley T, et al. Validation of the NPI-Q, a brief clinical form of the Neuropsychiatric Inventory. J Neuropsychiatry Clin Neurosci. 2000;12(2):233–9.

  45. 45.

    Logsdon RG, Gibbons LE, McCurry SM, Teri L. Assessing quality of life in older adults with cognitive impairment. Psychosom Med. 2002;64(3):510–9.

  46. 46.

    Gruters AAA, Ramakers IHGB, De Vugt ME, Kessels RPC, Blom M, Bouwman FH, et al. GeheugenpoliMonitor 2016. Maastricht: Alzheimer Centrum Limburg; 2018.

  47. 47.

    Erlen JA, Tamres LK, Reynolds N, Golin CE, Rosen MI, Remien RH, et al. Assessing usual care in clinical trials. West J Nurs Res. 2015;37(3):288–98.

  48. 48.

    Gitlin LN, Kales HC, Lyketsos CG. Managing behavioral symptoms in dementia using nonpharmacologic approaches: an overview. JAMA. 2012;308(19):2020–9.

  49. 49.

    Kales HC, Gitlin LN, Lyketsos C. DICE APPROACH: guiding the caregiver in managing the behavioral symptoms of dementia. Ann Arbor: Michigan Publishing; 2019.

  50. 50.

    Miller MD, Paradis CF, Houck PR, Mazumdar S, Stack JA, Rifai AH, et al. Rating chronic medical illness burden in geropsychiatric practice and research: application of the Cumulative Illness Rating Scale. Psychiatry Res. 1992;41(3):237–48.

  51. 51.

    Whitlatch CJ, Schur D, Noelker LS, Ejaz FK, Looman WJ. The stress process of family caregiving in institutional settings. The Gerontologist. 2001;41(4):462–73.

  52. 52.

    Schroevers MJ, Sanderman R, van Sonderen E, Ranchor AV. The evaluation of the Center for Epidemiologic Studies Depression (CES-D) scale: depressed and positive affect in cancer patients and healthy reference subjects. Qual Life Res. 2000;9(9):1015–29.

  53. 53.

    Brouwer WB, van Exel NJ, van Gorp B, Redekop WK. The CarerQol instrument: a new instrument to measure care-related quality of life of informal caregivers for use in economic evaluations. Qual Life Res. 2006;15(6):1005–21.

  54. 54.

    Alzheimer Nederland, Vilans. Zorgstandaard dementie. Alzheimer Nederland & Vilans; 2013.

  55. 55.

    Wind AW, Gussekloo J, Vernooij-Dassen M, Bouma M, Boomsma LJ, Boukes FS. NHG-standaard dementie. NHG-Standaarden 2009. Houten: Springer; 2009. p. 497–520.

  56. 56.

    Nederlandse Vereniging voor Klinische Geriatrie. In: Van Gool WA, Hagemeijer A, Barkhof F, Brouwer KJ, Eefsting JA, editors. Richtlijn diagnostiek en medicamenteuze behandeling van dementie. Utrecht: Nederlandse Vereniging voor Klinische Geriatrie; 2005.

  57. 57.

    Hughes CP, Berg L, Danziger WL, Coben LA, Martin RL. A new clinical scale for the staging of dementia. Br J Psychiatry. 1982;140:566–72.

  58. 58.

    Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12(3):189–98.

  59. 59.

    Brand N, Jolles J. Learning and retrieval rate of words presented auditorily and visually. J Gen Psychol. 1985;112(2):201–10.

  60. 60.

    Lindeboom J, Schmand B, Tulner L, Walstra G, Jonker C. Visual association test to detect early dementia of the Alzheimer type. J Neurol Neurosurg Psychiatry. 2002;73(2):126–33.

  61. 61.

    Wechsler D, Coalson DL, Raiford SE. WAIS-III: Wechsler adult intelligence scale. San Antonio: Psychological Corporation; 1997.

  62. 62.

    Van Der Elst WIM, Van Boxtel MPJ, Van Breukelen GJP, Jolles J. Normative data for the animal, profession and letter M naming verbal fluency tests for Dutch speaking participants and the effects of age, education, and sex. J Int Neuropsychol Soc. 2006;12(1):80–9.

  63. 63.

    Van der Elst W, van Boxtel MPJ, van Breukelen GJP, Jolles J. The Letter Digit Substitution Test: normative data for 1,858 healthy participants aged 24–81 from the Maastricht Aging Study (MAAS): influence of age, education, and sex. J Clin Exp Neuropsychol. 2006;28(6):998–1009.

  64. 64.

    Van der Elst W, Van Boxtel MP, Van Breukelen GJ, Jolles J. Detecting the significance of changes in performance on the Stroop Color-Word Test, Rey’s Verbal Learning Test, and the Letter Digit Substitution Test: the regression-based change approach. J Int Neuropsychol Soc. 2008;14(1):71–80.

  65. 65.

    Reitan RM. Validity of the Trail Making Test as an indicator of organic brain damage. Percept Mot Skills. 1958;8(3):271–6.

  66. 66.

    Sikkes SA, Knol DL, Pijnenburg YA, de Lange-de Klerk ES, Uitdehaag BM, Scheltens P. Validation of the Amsterdam IADL Questionnaire©, a new tool to measure instrumental activities of daily living in dementia. Neuroepidemiology. 2013;41(1):35–41.

  67. 67.

    Logsdon RG, Gibbons LE, McCurry SM, Teri L. Quality of life in Alzheimer’s disease: patient and caregiver reports. J Mental Health Aging. 1999;5:21–32.

  68. 68.

    Kraijo H, Brouwer W, de Leeuw R, Schrijvers G, van Exel J. The perseverance time of informal carers of dementia patients: validation of a new measure to initiate transition of care at home to nursing home care. J Alzheimers Dis. 2014;40(3):631–42.

  69. 69.

    Gitlin LN, Kales HC, Marx K, Stanislawski B, Lyketsos C. A randomized trial of a web-based platform to help families manage dementia-related behavioral symptoms: the WeCareAdvisor. Contemp Clin Trials. 2017;62:27–36.

  70. 70.

    Herdman M, Gudex C, Lloyd A, Janssen MF, Kind P, Parkin D, et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res. 2011;20(10):1727–36.

  71. 71.

    Flynn TN, Chan P, Coast J, Peters TJ. Assessing quality of life among British older people using the ICEPOP CAPability (ICECAP-O) measure. Appl Health Econ Health Policy. 2011;9(5):317–29.

  72. 72.

    Hoefman RJ, Van Exel NJA, Brouwer WBF. iMTA valuation of informal care questionnaire (iVICQ) 2011. Available from: https://www.imta.nl/questionnaires/.

  73. 73.

    Bouwmans C, Hakkaart-van Roijen L, Koopmanschap M, Krol M, Severens H, Brouwer W. Handleiding iMTA Medical Consumption Questionnaire (iMCQ). Rotterdam: iMTA, Erasmus Universiteit Rotterdam; 2013.

  74. 74.

    Cohen-Mansfield J, Marx MS, Rosenthal AS. A description of agitation in a nursing home. J Gerontol. 1989;44(3):77–84.

  75. 75.

    Marin RS, Biedrzycki RC, Firinciogullari S. Reliability and validity of the Apathy Evaluation Scale. Psychiatry Res. 1991;38(2):143–62.

  76. 76.

    Alexopoulos GS, Abrams RC, Young RC, Shamoian CA. Cornell Scale for Depression in Dementia. Biol Psychiatry. 1988;23(3):271–84.

  77. 77.

    Shankar KK, Walker M, Frost D, Orrell MW. The development of a valid and reliable scale for rating anxiety in dementia (RAID). Aging Ment Health. 1999;3(1):39–49.

  78. 78.

    Reisberg B, Borenstein J, Salob SP, Ferris SH, Franssen E, Georgotas A. Behavioral symptoms in Alzheimer’s disease: phenomenology and treatment. J Clin Psychiatry. 1987;48(5, suppl):9–15.

  79. 79.

    Tractenberg RE, Singer CM, Cummings JL, Thal LJ. The Sleep Disorders Inventory: an instrument for studies of sleep disturbance in persons with Alzheimer’s disease. J Sleep Res. 2003;12(4):331–7.

  80. 80.

    Bowling A, Rowe G, Adams S, Sands P, Samsi K, Crane M, et al. Quality of life in dementia: a systematically conducted narrative review of dementia-specific measurement scales. Aging Ment Health. 2015;19(1):13–31.

  81. 81.

    Hongisto K, Hallikainen I, Selander T, Tormalehto S, Vaatainen S, Martikainen J, et al. Quality of life in relation to neuropsychiatric symptoms in Alzheimer’s disease: 5-year prospective ALSOVA cohort study. Int J Geriatr Psychiatry. 2018;33(1):47–57.

  82. 82.

    de Jonghe JF, Kat MG. Factor structure and validity of the Dutch version of the Cohen-Mansfield Agitation Inventory (CMAI-D). J Am Geriatr Soc. 1996;44(7):888–9.

  83. 83.

    Richters A, Melis RJ, van Exel NJ, Olde Rikkert MG, van der Marck MA. Perseverance time of informal caregivers for people with dementia: construct validity, responsiveness and predictive validity. Alzheimers Res Ther. 2017;9(1):26.

  84. 84.

    Patton MQ. Qualitative research & evaluation methods: integrating theory and practice; 2015.

  85. 85.

    Millenaar JK, van Vliet D, Bakker C, Vernooij-Dassen MJ, Koopmans RT, Verhey FR, et al. The experiences and needs of children living with a parent with young onset dementia: results from the NeedYD study. Int Psychogeriatr. 2014;26(12):2001–10.

  86. 86.

    Sorensen LV, Waldorff FB, Waldemar G. Early counselling and support for patients with mild Alzheimer’s disease and their caregivers: a qualitative study on outcome. Aging Ment Health. 2008;12(4):444–50.

  87. 87.

    Guo Y, Logan HL, Glueck DH, Muller KE. Selecting a sample size for studies with repeated measures. BMC Med Res Methodol. 2013;13:100.

  88. 88.

    Karlawish J, Cary MS, Rubright J, Tenhave T. How redesigning AD clinical trials might increase study partners’ willingness to participate. Neurology. 2008;71(23):1883–8.

  89. 89.

    Gupta SK. Intention-to-treat concept: a review. Perspect Clin Res. 2011;2(3):109–12.

  90. 90.

    Tan SS, Bouwmans CA, Rutten FF, Hakkaart-van Roijen L. Update of the Dutch manual for costing in economic evaluations. Int J Technol Assess Health Care. 2012;28(2):152–8.

  91. 91.

    Bravo Vergel Y, Sculpher M. Quality-adjusted life years. Pract Neurol. 2008;8(3):175–82.

  92. 92.

    Evers JC. Elaborating on thick analysis: about thoroughness and creativity in qualitative analysis. FQS. 2016;17(1).

  93. 93.

    Elo S, Kyngäs H. The qualitative content analysis process. J Adv Nurs. 2008;62(1):107–15.

  94. 94.

    Scales K, Zimmerman S, Miller SJ. Evidence-based nonpharmacological practices to address behavioral and psychological symptoms of dementia. Gerontologist. 2018;58(suppl_1):S88–S102.

  95. 95.

    Schulz R, O’Brien A, Czaja S, Ory M, Norris R, Martire LM, et al. Dementia caregiver intervention research: in search of clinical significance. Gerontologist. 2002;42(5):589–602.

  96. 96.

    Zarit SH. Past is prologue: how to advance caregiver interventions. Aging Ment Health. 2018;22(6):717–22.

  97. 97.

    Mittelman MS. Psychosocial intervention research: challenges, strategies and measurement issues. Aging Ment Health. 2008;12(1):1–4.

Download references

Acknowledgements

Not applicable.

Funding

This project was supported by an Alzheimer Nederland and Memorabel ZonMw Grant 733050823 (Deltaplan Dementie) to JMP and RO.

Availability of data and materials

Not applicable.

Author information

Affiliations

  1. Department of Neurology, Erasmus MC University Medical Center, PO Box 2040, 3000 CA, Rotterdam, the Netherlands

    • Willem S. Eikelboom
    • , Esther van den Berg
    • , Frank Jan de Jong
    • , John C. van Swieten
    •  & Janne M. Papma

  2. Department of Neurology, Alzheimer Center Amsterdam, Amsterdam University Medical Center, PO Box 7057, 1007 MB, Amsterdam, the Netherlands

    • Ellen Singleton
    • , Yolande A. L. Pijnenburg
    • , Philip Scheltens
    •  & Rik Ossenkoppele

  3. Department of Psychiatry, Erasmus MC University Medical Center, PO Box 2040, 3000 CA, Rotterdam, the Netherlands

    • Michiel Coesmans

  4. Department of Internal Medicine, Erasmus MC University Medical Center, PO Box 2040, 3000 CA, Rotterdam, the Netherlands

    • Francesco Mattace Raso
    • , Rozemarijn L. van Bruchem
    •  & Jeannette A. Goudzwaard

  5. Erasmus School of Health Policy & Management, Erasmus University, PO Box 1738, 3000 DR, Rotterdam, the Netherlands

    • Marc Koopmanschap

  6. Department of Neurology, Franciscus Gasthuis, PO Box 10900, 3004 BA, Rotterdam, the Netherlands

    • Tom den Heijer

  7. Department of Neurology, Franciscus Vlietland, PO Box 215, 3100 AE, Schiedam, the Netherlands

    • Jan J. M. Driesen

  8. Department of Neurology, Het Van Weel-Bethesda Ziekenhuis, PO Box 153, 3240 AD, Dirksland, the Netherlands

    • Lilian J. H. M. Vroegindeweij

  9. Department of Neurology, Maasstad Hospital, PO Box 9100, 3007 AC, Rotterdam, the Netherlands

    • Elsbeth C. Thomeer

  10. Department of Neurology, Spijkenisse Medical Center, PO Box 777, 3200 GA, Spijkenisse, the Netherlands

    • Susanne E. Hoogers

  11. Department of Anatomy and Neurosciences, Amsterdam University Medical Center, PO Box 7057, 1007 MB, Amsterdam, the Netherlands

    • Anke A. Dijkstra

  12. Department of General Practice and Elderly Care Medicine, University of Groningen, University Medical Center Groningen, PO Box 30,001, 9700 RB, Groningen, the Netherlands

    • Sytse U. Zuidema

  13. Clinical Memory Research Unit, Lund University, Simrisbanvägen 14, 212 24, Malmö, Sweden

    • Rik Ossenkoppele

Authors

  1. Search for Willem S. Eikelboom in:

  2. Search for Ellen Singleton in:

  3. Search for Esther van den Berg in:

  4. Search for Michiel Coesmans in:

  5. Search for Francesco Mattace Raso in:

  6. Search for Rozemarijn L. van Bruchem in:

  7. Search for Jeannette A. Goudzwaard in:

  8. Search for Frank Jan de Jong in:

  9. Search for Marc Koopmanschap in:

  10. Search for Tom den Heijer in:

  11. Search for Jan J. M. Driesen in:

  12. Search for Lilian J. H. M. Vroegindeweij in:

  13. Search for Elsbeth C. Thomeer in:

  14. Search for Susanne E. Hoogers in:

  15. Search for Anke A. Dijkstra in:

  16. Search for Sytse U. Zuidema in:

  17. Search for Yolande A. L. Pijnenburg in:

  18. Search for Philip Scheltens in:

  19. Search for John C. van Swieten in:

  20. Search for Rik Ossenkoppele in:

  21. Search for Janne M. Papma in:

Contributions

JMP and RO acquired funding for the BEAT-IT study. JMP, WSE, RO, ES, and JCS designed the study in consultation with FMR, RLB, JAG, FJJ, TH, JJMD, LJHMV, ECT, and SEH who also contributed to the “Methods” section of this manuscript. WSE coordinates the intervention study under the supervision of JMP, RO, and JCS. WSE, FMR, RLB, JAG, FJJ, TH, JJMD, LJHMV, ECT, SEH, and JCS will be responsible for patient inclusion. EB, MC, JMP, and WSE will carry out the DICE method. ES coordinates the prospective cohort of bvAD patients under the supervision of RO, JMP, YALP, and PS. WSE, RO, and JMP wrote the first version of the manuscript. ES, AAD, MK, EB, MC, and SUZ critically reviewed the paper. All authors read and approved the final version of the manuscript.

Corresponding author

Correspondence to Janne M. Papma.

Ethics declarations

Ethics approval and consent to participate

This study is approved by the Medical Ethics Committee (METC) of the Erasmus Medical Center in the Netherlands (MEC-2018-1443). This research will be executed according to the code of conduct of the Dutch Medical Research Involving Human Subjects Act (WMO) and the principles of the Declaration of Helsinki (version 7, 2013). Written informed consent will be obtained from all subjects before study inclusion.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Keywords

  • Alzheimer’s disease
  • Dementia
  • Behavior
  • Caregivers
  • Neuropsychiatry
  • Cost-benefit analysis
  • Prospective studies
  • Quality of life

Alzheimer's Research & Therapy

ISSN: 1758-9193